These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648 [TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272 [TBL] [Abstract][Full Text] [Related]
4. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Appelbaum FR Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531 [TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies. Gaut D; Mead M Leuk Lymphoma; 2021 Jan; 62(1):8-31. PubMed ID: 33138674 [TBL] [Abstract][Full Text] [Related]
7. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? Araki D; Wood BL; Othus M; Radich JP; Halpern AB; Zhou Y; Mielcarek M; Estey EH; Appelbaum FR; Walter RB J Clin Oncol; 2016 Feb; 34(4):329-36. PubMed ID: 26668349 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162 [TBL] [Abstract][Full Text] [Related]
11. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. Appelbaum FR Best Pract Res Clin Haematol; 2015; 28(2-3):133-40. PubMed ID: 26590770 [TBL] [Abstract][Full Text] [Related]
12. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation. Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275 [TBL] [Abstract][Full Text] [Related]
13. Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML. Orvain C; Ali N; Othus M; Rodríguez-Arbolí E; Milano F; Le CM; Sandmaier BM; Scott BL; Appelbaum FR; Walter RB Am J Hematol; 2024 May; 99(5):862-870. PubMed ID: 38380817 [TBL] [Abstract][Full Text] [Related]
15. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation]. Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035 [No Abstract] [Full Text] [Related]
16. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321 [TBL] [Abstract][Full Text] [Related]
17. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation. Wang L; Shu M; Zhang Z; Dou X; Xu X; Ma Y; Wen L; Yang X; Chen S J Cancer Res Clin Oncol; 2024 Oct; 150(10):465. PubMed ID: 39422784 [TBL] [Abstract][Full Text] [Related]
19. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089 [TBL] [Abstract][Full Text] [Related]